Kanyos Bio

Biotechnology, Health Care, Life Science
Founded in 2015-01-01
Cambridge, Massachusetts, United States
http://kanyos.com
For Profit

About Kanyos Bio

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. Kanyos and Anokion are collaborating in this effort with Astellas Pharma, Inc. (“Astellas”). As an independent affiliate, Kanyos aims to develop antigen-specific, disease-modifying therapies for patients with type-1 diabetes and celiac disease by leveraging the immunotechnology expertise of Anokion and the clinical translation experience of Astellas.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: None
  • Tech Stack: 11 active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 26799752 USD
  • Last Funding: 16399876 USD (Venture - Series Unknown)
  • Funding Status: M&A

Technology Stack

Kanyos Bio actively uses 11 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Life Science

Headquarters: Cambridge, Massachusetts, United States